Ataraxis AI has launched Ataraxis Breast CTX, an AI test that predicts individualized chemotherapy benefit for breast cancer patients. The tool uses digital pathology and clinical data to estimate patient-level outcomes with and without chemotherapy, moving beyond population averages. The test has been validated across studies involving over 10,000 patients and is now available through CLIA-certified laboratories.
The FDA has accepted Roche's new drug application for giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer, with a decision expected by December 18, 2026.
The FDA has accepted Roche's New Drug Application for giredestrant plus everolimus to treat ESR1-mutated, ER-positive advanced breast cancer, with a decision expected by December 18, 2026. The filing is based on phase III data showing significant reductions in disease progression risk.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07596212 |
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07589699 |
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP |
NOT_YET_RECRUITING | PHASE4 |
| NCT07483996 |
Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07366112 |
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment |
NOT_YET_RECRUITING | PHASE2 |
| NCT07215364 |
Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors |
NOT_YET_RECRUITING | NA |
| NCT07178665 |
Pilot Trial of Preop Partial Radiation in Breast Cancer Patients |
SUSPENDED | PHASE1 |
| NCT06970912 |
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer |
RECRUITING | PHASE2 |
| NCT06902311 |
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) |
RECRUITING | PHASE2 |
| NCT06650748 |
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT06536881 |
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming |
RECRUITING | NA |
